90 results on '"Ceruti R"'
Search Results
2. Retrovirus-mediated IL-4 gene therapy in spontaneous adenocarcinomas from MMTV-neu transgenic mice
- Author
-
Sacco, M G, Benedetti, S, Catò, E Mira, Caniatti, M, Ceruti, R, Scanziani, E, Pirola, B, Villa, A, Finocchiaro, G, and Vezzoni, P
- Published
- 1999
- Full Text
- View/download PDF
3. Studio dell’effetto filiera sull’epidemiologia molecolare di QX in Italia
- Author
-
Tucciarone, C. M., Franzo, G., Legnardi, M., Massi, P., Tosi, G., Trogu, T., GUTIERREZ GARCIA-MORENO, Anna, Ceruti, R., Pesente, P., Ortali, G., Gavazzi, L., and Cecchinato, M.
- Published
- 2019
4. Correlation between fine-needle aspiration cytology and histopathology in the evaluation of cutaneous and subcutaneous masses from dogs and cats
- Author
-
Ghisleni, G., Roccabianca, P., Ceruti, R., Stefanello, D., Bertazzolo, W., Bonfanti, U., and Caniatti, M.
- Published
- 2006
- Full Text
- View/download PDF
5. The polo-like kinase 1 (PLK1) inhibitor NMS-P937 is \ud effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia
- Author
-
Casolaro, A., Golay, J., Albanese, C., Ceruti, R., Patton, V., Cribioli, S., Pezzoni, A., Losa, M., Texido, G., Giussani, U., Marchesi, F., Amboldi, N., Valsasina, B., Bungaro, S., Cazzaniga, G., Rambaldi, A., Introna, M., Pesenti, E., and Alzani, R.
- Subjects
hemic and lymphatic diseases - Abstract
CD56 is expressed in 15–20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML (AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56+ monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST = 28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56+ AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML.
- Published
- 2013
6. 31 N-Myc amplification sensitizes tumor cells to inhibition by Danusertib, an Aurora kinase inhibitor
- Author
-
Carpinelli, P., primary, Ceruti, R., additional, Alzani, R., additional, Re, C., additional, Ballinari, D., additional, Cribioli, S., additional, Russo, M., additional, Degrassi, A., additional, Texido, G., additional, Ciomei, M., additional, Pesenti, E., additional, Montagnoli, A., additional, and Galvani, A., additional
- Published
- 2014
- Full Text
- View/download PDF
7. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia
- Author
-
Casolaro, A, Golay, J, Albanese, C, Ceruti, R, Patton, V, Cribioli, S, Pezzoni, A, Losa, M, Texido, G, Giussani, U, Marchesi, F, Amboldi, N, Valsasina, B, Bungaro, S, Cazzaniga, G, Rambaldi, A, Introna, M, Pesenti, E, Alzani, R, Casolaro, Alessia, Golay, Josee, Albanese, Clara, Ceruti, Roberta, Patton, Veronica, Cribioli, Sabrina, Pezzoni, Alice, Losa, Marco, Texido, Gemma, Giussani, Ursula, Marchesi, Francesco, Amboldi, Nadia, Valsasina, Barbara, Bungaro, Silvia, Cazzaniga, Giovanni, Rambaldi, Alessandro, Introna, Martino, Pesenti, Enrico, Alzani, Rachele, Casolaro, A, Golay, J, Albanese, C, Ceruti, R, Patton, V, Cribioli, S, Pezzoni, A, Losa, M, Texido, G, Giussani, U, Marchesi, F, Amboldi, N, Valsasina, B, Bungaro, S, Cazzaniga, G, Rambaldi, A, Introna, M, Pesenti, E, Alzani, R, Casolaro, Alessia, Golay, Josee, Albanese, Clara, Ceruti, Roberta, Patton, Veronica, Cribioli, Sabrina, Pezzoni, Alice, Losa, Marco, Texido, Gemma, Giussani, Ursula, Marchesi, Francesco, Amboldi, Nadia, Valsasina, Barbara, Bungaro, Silvia, Cazzaniga, Giovanni, Rambaldi, Alessandro, Introna, Martino, Pesenti, Enrico, and Alzani, Rachele
- Abstract
CD56 is expressed in 15-20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML (AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56(+) monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST = 28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56(+) AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML.
- Published
- 2013
8. 363 POSTER In vitro and in vivo molecular characterization of PHA-739358, an inhibitor of Aurora kinases
- Author
-
Carpinelli, P., primary, Ceruti, R., additional, Degrassi, A., additional, Fancelli, D., additional, Gianellini, L., additional, Marsiglio, A., additional, Croci, V., additional, Rocchetti, M., additional, Texido, G., additional, and Moll, J., additional
- Published
- 2006
- Full Text
- View/download PDF
9. Enterobacter cloacaein an Italian Neonatal Intensive Care Unit: Pattern of Drug Resistance Compared with an International Database (SENTRY Antimicrobial Surveillance Program)
- Author
-
Tomasoni, D., primary, Gattuso, G., additional, Scalzini, A., additional, Ceruti, R., additional, Chiarelli, C., additional, Stradoni, R., additional, Bottura, C., additional, and Berra, D., additional
- Published
- 2006
- Full Text
- View/download PDF
10. MultiresistantStenotrophomonas maltophiliaTunneled CVC-Related Sepsis, Treated with Systemic and Lock Therapy
- Author
-
Gattuso, G., primary, Tomasoni, D., additional, Ceruti, R., additional, and Scalzini, A., additional
- Published
- 2004
- Full Text
- View/download PDF
11. Prevalence of T cell receptor ζchain deficiency in systemic lupus erythematosus
- Author
-
Nambiar, M P, primary, Mitchell, J P, additional, Ceruti, R P, additional, Malloy, M A, additional, and Tsokos, G C, additional
- Published
- 2003
- Full Text
- View/download PDF
12. Cytological features of canine haemangiopericytoma in fine needle aspiration biopsy
- Author
-
Caniatti, M., primary, Ghisleni, G., additional, Ceruti, R., additional, Roccabianca, P., additional, and Scanziani, E., additional
- Published
- 2001
- Full Text
- View/download PDF
13. Capillaria hepatica Infection in Wild Brown Rats (Rattus norvegicus) from the Urban Area of Milan, Italy
- Author
-
Ceruti, R., primary, Sonzogni, O., additional, Origgi, F., additional, Vezzoli, F., additional, Cammarata, S., additional, Giusti, A. M., additional, and Scanziani, E., additional
- Published
- 2001
- Full Text
- View/download PDF
14. Verifying the Strength of a Shrink Fit Joint for the RHIC Post Leg
- Author
-
Brown, D. P., primary, Gibbs, R. J., additional, Wu, K. C., additional, and Ceruti, R. B., additional
- Published
- 1988
- Full Text
- View/download PDF
15. Application of echo--Cancelling techniques to audioconference.
- Author
-
Ceruti, R. and Pira, F.
- Published
- 1982
- Full Text
- View/download PDF
16. What's new in streptococcal pharyngitis
- Author
-
Boccazzi, A., Tonelli, P., and Ceruti, R.
- Published
- 2000
- Full Text
- View/download PDF
17. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity
- Author
-
Gatto, C., Rieppi, M., Borsotti, P., Innocenti, S., Ceruti, R., Drudis, T., Eugenio Scanziani, Casazza, A. M., Taraboletti, G., and Giavazzi, R.
- Subjects
Umbilical Veins ,Dose-Response Relationship, Drug ,Neovascularization, Pathologic ,Biphenyl Compounds ,Neovascularization, Physiologic ,Angiogenesis Inhibitors ,Antineoplastic Agents ,Matrix Metalloproteinase Inhibitors ,Phenylbutyrates ,Mice, Inbred C57BL ,Drug Combinations ,Mice ,Animals ,Humans ,Fibroblast Growth Factor 2 ,Proteoglycans ,Collagen ,Endothelium, Vascular ,Laminin ,Organic Chemicals ,Cell Division ,Cells, Cultured - Abstract
Matrix metalloproteinases (MMPs) have been implicated in tumor cell invasion, metastasis, and angiogenesis. BAY 12-9566, a novel, non-peptidic biphenyl MMP inhibitor, has shown preclinical activity on a broad range of tumor models and is currently in clinical development. The purpose of this study was to investigate the antiangiogenic activity of BAY 12-9566. In vitro, BAY 12-9566 prevented matrix invasion by endothelial cells in a concentration-dependent manner (IC50 = 8.4x10(-7) M), without affecting cell proliferation. In vivo, oral daily administration of BAY 12-9566 (50-200 mg/kg) inhibited angiogenesis induced by basic fibroblast growth factor in the Matrigel plug assay, reducing the hemoglobin content of the pellets. Histological analysis showed a reduction in the amount of functional vessels within the Matrigel. We conclude that the MMP inhibitor BAY 12-9566 inhibits angiogenesis, a property that further supports its clinical development as an antimetastatic agent.
18. Liposome-delivered angiostatin strongly inhibits tumor growth and metastatization in a transgenic model of spontaneous breast cancer
- Author
-
Sacco, M. G., Mario Caniatti, Catò, E. M., Frattini, A., Chiesa, G., Ceruti, R., Adorni, F., Zecca, L., Scanziani, E., and Vezzoni, P.
- Subjects
Receptor, ErbB-2 ,Mammary Neoplasms, Experimental ,Membrane Proteins ,Antineoplastic Agents ,Mice, Transgenic ,Plasminogen ,Genetic Therapy ,Peptide Fragments ,Mice ,Liposomes ,Animals ,Humans ,Receptors, Virus ,Female ,Neoplasm Metastasis ,Angiostatins - Abstract
The possibility to inhibit tumor growth by interfering with the formation of new vessels, which most neoplasias depend on, has recently raised considerable interest. An angiogenic switch, in which proliferating cells acquire the ability to direct new vessel formation, is thought to be an early step in the natural history of solid tumors. Using a transgenic model of breast cancer, which shows many similarities to its human counterpart, including ability to metastasize, we targeted angiostatin production to an early stage of tumor formation. Liposome-delivered angiostatin considerably delayed primary tumor growth and, more importantly, inhibited the appearance of lung metastases. These findings can be relevant to the design of therapeutic intervention in humans.
19. Use of flow cytometry for drug development of cell cycle inhibitor: The example of edotecarion, a topoisomerase I inhibitor
- Author
-
Paolo Elia Cappella, Patton, V., Albanese, C., Alzani, R., Ceruti, R., and Ciomei, M.
20. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease
- Author
-
Radaelli, E., Ceruti, R., Patton, V., Russo, M., Degrassi, A., Croci, V., Caprera, F., Stortini, G., Eugenio Scanziani, Pesenti, E., and Alzani, R.
- Subjects
616 - Patología. Medicina clínica. Oncología ,Hypoxiainducible ,Glioblastoma - Abstract
Tumorigenesis in human glioblastoma multiforme (GBM) is driven by several genetic abnormalities with disruption of important molecular pathways, such as p53/MDM2/p14ARF and EGFR/PTEN/Akt/mTOR. The malignant progression of human GBM is also primarily associated with a peculiar multistep pathophysiological process characterized by intratumoral ischemic necrosis (i.e. pseudopalisading necrosis) and activation of the hypoxia-inducible factor (HIF)-1a pathway with consequent peritumoral microvascular proliferation and infiltrative behaviour. Predictable preclinical animal models of GBM should recapitulate the main pathobiological hallmarks of the human disease. In this study we describe two murine orthotopic xenograft models using U87MG and U251 human cell lines. Ten Balb/c nude male mice were orthotopically implanted with either U87MG (5 mice) or U251 (5 mice) cell lines. Intracranial tumor growth was monitored through Magnetic Resonance Imaging (MRI). Immunohistopathological examination of the whole cranium was performed 30 days after implantation. U251 orthotopic xenografts recapitulated the salient pathobiological features described for human GBM, including invasive behaviour, wide areas of pseudopalisading necrosis, florid peripheral angiogenesis, GFAP and vimentin expression, nonfunctional p53 expression, striking active-caspase-3 and HIF-1a expression along pseudopalisades. U87MG orthotopic xenografts proved to be very dissimilar from human GBM, showing expansile growth, occasional necrotic foci without pseudopalisades, intratumoral lacunar pattern of angiogenesis, lack of GFAP expression, fuctional p53 expression and inconsistent HIF-1a expression. Expression of pAkt was upregulated in both models. The results obtained suggest that the U251 orthotopic model may be proposed as a predictive and reliable tool in preclinical studies since it recapitulates the most salient pathobiological features reported for human GBM.
21. Virulence - Associated genes in Avian Pathogenic Escherichia coli of Turkey | Geni di virulenza in Avian Pathogenic Escherichia coli nel Tacchino
- Author
-
Elena Circella, Pennelli, D., Tagliabue, S., Ceruti, R., Giovanardi, D., and Camarda, A.
22. Ringtail in suckling Munich Wistar Fromter rats: A histopathologic study
- Author
-
Crippa, L., Gobbi, A., Ceruti, R. M., Clifford, C. B., Andrea Remuzzi, and Scanziani, E.
- Subjects
Male ,Tail ,Epidermal DNA-synthesism ,mice ,hyperkeratosis ,Histocytochemistry ,MWF rats ,proteinuria ,mouse ,Settore ING-IND/34 - Bioingegneria Industriale ,Skin Diseases ,Animals, Suckling ,Rats ,Rodent Diseases ,Animals ,Female ,Dietary Proteins ,Rats, Wistar - Abstract
Ringtail is a pathologic condition of the tail of rats and other rodents that is traditionally attributed to low environmental humidity, although dietary deficiencies, genetic susceptibility, environmental temperature, and degree of hydration of the animal also have been suggested as possible causes. To the authors' knowledge, a detailed histopathologic study that may serve to shed light on the etiopathogenesis of this disease has not yet been published. We describe the histologic findings of ringtail observed in 12 suckling Munich Wistar Fromter (MWF) rats from two litters. Epidermal hyperplasia characterized by orthokeratotic and parakeratotic hyperkeratosis and acanthosis was observed in all affected rats. Numerous often dilated vessels were present in the dermis of tails that appeared of red/brown color at gross examination. In severe cases, the dilated vascular structures were thrombotic and accompanied by dermal hemorrhages and focal coagulative necrosis of the overlying epidermis. These findings suggest that epidermal acanthosis and hyperkeratosis are the main and primary events in the development of ringtail. To clarify the cause of this disease, future studies should be focused on the numerous factors that can induce such epidermal changes.
23. Stroke and rehabilitation: Italian Cooperative Research (ICR2)
- Author
-
Franceschini, M., Branchini, W., Rodolfo Brianti, Camillis, E., Ferrari, L., Galvagni, R., Lenti, G., Manca, M., Mayer, F., Molteni, F., Perdon, L., Procicchiani, D., Todeschini, E., Zaccala, M., Agosti, M., Casella, G., Celani, M. G., Citterio, A., Masucci, M., Spizzichino, L., Vallasciani, M., Recupero, E., Finocchiaro, F., Santagati, A., Greco, S., Longo, P., Comessatti, C., Taroni, B., Cosentino, E., Biondi, T., Mugelli, C., Maria Rossi, R., Serra, A., Bertoni, M., Meinecke, C., Fabbrini, S., Confalonieri, D., Ceruti, R., Fortina, C., Zaccaria, B., Meneghetti, S., Robuschi, K., Michelotti, V., Cavaldonati, A., Sandrini, G., Arrigo, A., Antenucci, R., Gandolfi, P., Gatta, G., Boschini, L., Dardani, M., Massucci, M., Braconi, A. R., Bortoluzzi, N., and Timar, J.
24. A New Approach to a Multifrequential Impedance Measurement
- Author
-
Arslan, E., primary, Canavesio, F., additional, and Ceruti, R., additional
- Published
- 1979
- Full Text
- View/download PDF
25. Application of echo--Cancelling techniques to audioconference
- Author
-
Ceruti, R., primary and Pira, F., additional
- Full Text
- View/download PDF
26. Verifying the Strength of a Shrink Fit Joint for the RHIC Post Leg
- Author
-
Ceruti, R. [Brookhaven National Lab. (BNL), Upton, NY (United States)]
- Published
- 1988
- Full Text
- View/download PDF
27. Clostridioides difficile in Pigs and Dairy Cattle in Northern Italy: Prevalence, Characterization and Comparison between Animal and Human Strains.
- Author
-
Spigaglia P, Barbanti F, Faccini S, Vescovi M, Criscuolo EM, Ceruti R, Gaspano C, and Rosignoli C
- Abstract
It has been observed that novel strains of Clostridioides difficile can rapidly emerge and move between animal and human hosts. The aim of this study was to investigate the prevalence of C. difficile in pigs and dairy cattle in northern Italy and to characterize and compare C. difficile animal strains with those from patients from the same geographical area. The C. difficile strains were isolated from animals from farms and slaughterhouses (cross-sectional studies) and from neonatal animals with enteric disorders in routine diagnostic investigations (passive surveillance). Samples positive for C. difficile were found in 87% of the pig farms and in 40% of the cattle farms involved in the cross-sectional studies, with a 20% prevalence among suckling piglets and 6.7% prevalence in neonatal calves, with no significant difference between animals with and without diarrheal symptoms. The prevalence of C. difficile in older animal categories was significantly lower. This result suggests that young age is an important risk factor for C. difficile colonization. In cross-sectional studies at slaughterhouses, in both the heavy pigs and dairy cows examined, only 2% of the intestinal content samples were positive for C. difficile and no contamination was found on the surface of the carcasses. Considering passive surveillance, the prevalence rates of positive samples were 29% in piglets and 1.4% in calves. Overall, 267 strains of animal origin and 97 from humans were collected. In total, 39 ribotypes (RTs) were identified, with RT 078 and RT 018 being predominant among animals and humans, respectively. Several RTs overlapped between animals and patients. In particular, RT 569 was identified as an emergent type in our country. Resistance to erythromycin and moxifloxacin was widely diffused among C. difficile strains, regardless of origin. This study supports C. difficile as a pathogen of one-health importance and highlights the need for a collaborative approach between physicians and veterinarians to control and prevent infections that are able to cross species and geographical barriers.
- Published
- 2023
- Full Text
- View/download PDF
28. Whole-Genome Sequence of Salmonella enterica Serovar Bispebjerg from Turkey Reveals Its Pathogenic Potential.
- Author
-
Tiengo A, Orsini M, Petrin S, Losasso C, Longo A, Cento G, Ciot L, Ceruti R, Cibin V, and Barco L
- Abstract
We report the genome sequence of a Salmonella enterica subsp. enterica serovar Bispebjerg strain that was isolated from a turkey flock in 2011. The genome analysis of the strain, a rare and multihost serovar, revealed its pathogenic potential due to antimicrobial resistance and a plethora of Salmonella pathogenicity islands and virulence factors., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
29. Bloody Diarrhea and Shiga Toxin-Producing Escherichia coli Hemolytic Uremic Syndrome in Children: Data from the ItalKid-HUS Network.
- Author
-
Ardissino G, Vignati C, Masia C, Capone V, Colombo R, Tel F, Daprai L, Testa S, Dodaro A, Paglialonga F, Luini M, Brigotti M, Picicco D, Baldioli C, Pagani F, Ceruti R, Tommasi P, Possenti I, Cresseri D, Consonni D, Montini G, and Arghittu M
- Subjects
- Adolescent, Child, Child, Preschool, Early Diagnosis, Escherichia coli Infections complications, Female, Gastrointestinal Hemorrhage diagnosis, Genes, Bacterial, Hemolytic-Uremic Syndrome diagnosis, Hemolytic-Uremic Syndrome epidemiology, Hemolytic-Uremic Syndrome therapy, Humans, Infant, Infant, Newborn, Italy, Male, Shiga Toxins genetics, Shiga-Toxigenic Escherichia coli genetics, Treatment Outcome, Young Adult, Diarrhea microbiology, Escherichia coli Infections diagnosis, Gastrointestinal Hemorrhage microbiology, Hemolytic-Uremic Syndrome microbiology, Mass Screening methods, Shiga-Toxigenic Escherichia coli isolation & purification
- Abstract
Objective: To analyze the results of an enhanced laboratory-surveillance protocol for bloody diarrhea aimed at identifying children with Shiga toxin-producing Escherichia coli (STEC) infection early in the course of the disease toward the early identification and management of patients with hemolytic uremic syndrome (HUS)., Study Design: The study (2010-2019) involved a referral population of 2.3 million children. Stool samples of patients with bloody diarrhea were screened for Shiga toxin (Stx) genes. Positive patients were rehydrated and monitored for hemoglobinuria until diarrhea resolved or STEC-HUS was diagnosed., Results: A total of 4767 children were screened; 214 (4.5%) were positive for either Stx1 (29.0%) or Stx2 (45.3%) or both Stx1+2 (25.7%); 34 patients (15.9%) developed STEC-HUS (0.71% of bloody diarrheas). Hemoglobinuria was present in all patients with HUS. Patients with Stx2 alone showed a greater risk of STEC-HUS (23.7% vs 12.7%) and none of the patients with Stx1 alone developed HUS. During the same period of time, 95 other patients were diagnosed STEC-HUS but were not captured by the screening program (26 had nonbloody diarrhea, 11 came from areas not covered by the screening program, and 58 had not been referred to the screening program, although they did meet the inclusion criteria). At HUS presentation, serum creatinine of patients identified by screening was significantly lower compared with that of the remaining patients (median 0.9 vs 1.51 mg/dL)., Conclusions: Nearly 1% of children with bloody diarrhea developed STEC-HUS, and its diagnosis was anticipated by the screening program for Stx. The screening of bloody diarrhea for Stx is recommended, and monitoring patients carrying Stx2 with urine dipstick for hemoglobinuria is suggested to identify the renal complication as early as possible., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
30. Phylodynamic analysis and evaluation of the balance between anthropic and environmental factors affecting IBV spreading among Italian poultry farms.
- Author
-
Franzo G, Tucciarone CM, Moreno A, Legnardi M, Massi P, Tosi G, Trogu T, Ceruti R, Pesente P, Ortali G, Gavazzi L, and Cecchinato M
- Subjects
- Animals, Farms, Italy, Chickens virology, Coronavirus Infections epidemiology, Coronavirus Infections genetics, Coronavirus Infections transmission, Coronavirus Infections veterinary, Genotype, Infectious bronchitis virus genetics, Infectious bronchitis virus pathogenicity, Phylogeny, Poultry Diseases epidemiology, Poultry Diseases genetics, Poultry Diseases transmission
- Abstract
Infectious bronchitis virus (IBV) control is mainly based on wide vaccine administration. Although effective, its efficacy is not absolute, the viral circulation is not prevented and some side effects cannot be denied. Despite this, the determinants of IBV epidemiology and the factors affecting its circulation are still largely unknown and poorly investigated. In the present study, 361 IBV QX (the most relevant field genotype in Italy) sequences were obtained between 2012 and 2016 from the two main Italian integrated poultry companies. Several biostatistical and bioinformatics approaches were used to reconstruct the history of the QX genotype in Italy and to assess the effect of different environmental, climatic and social factors on its spreading patterns. Moreover, two structured coalescent models were considered in order to investigate if an actual compartmentalization occurs between the two integrated poultry companies and the role of a third "ghost" deme, representative of minor industrial poultry companies and the rural sector. The obtained results suggest that the integration of the poultry companies is an effective barrier against IBV spreading, since the strains sampled from the two companies formed two essentially-independent clades. Remarkably, the only exceptions were represented by farms located in the high densely populated poultry area of Northern Italy. The inclusion of a third deme in the model revealed the likely role of other poultry companies and rural farms (particularly concentrated in Northern Italy) as sources of strain introduction into one of the major poultry companies, whose farms are mainly located in the high densely populated poultry area of Northern Italy. Accordingly, when the effect of different environmental and urban parameters on IBV geographic spreading was investigated, no factor seems to contribute to IBV dispersal velocity, being poultry population density the only exception. Finally, the different viral population pattern observed in the two companies over the same time period supports the pivotal role of management and control strategies on IBV epidemiology. Overall, the present study results stress the crucial relevance of human action rather than environmental factors, highlighting the direct benefits that could derive from improved management and organization of the poultry sector on a larger scale.
- Published
- 2020
- Full Text
- View/download PDF
31. An unusual neurological manifestation of granulomatosis with polyangiitis: A case report and literature review.
- Author
-
Tarte NN, Ceruti R, and Tati V
- Abstract
Ischemic stroke is an incredibly rare manifestation of granulomatosis with polyangiitis. It is important for the clinician to be aware of this unusual complication so that efforts can be made to reduce the risk of this event., Competing Interests: None declared., (© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2020
- Full Text
- View/download PDF
32. Effect of thermal treatment of whey contaminated with antibiotics on the growth of Kluyveromyces marxianus.
- Author
-
Eluk D, Ceruti R, Nagel O, and Althaus R
- Subjects
- Cephalosporins analysis, Cephalosporins chemistry, Culture Media chemistry, Drug Stability, Fermentation, Food Contamination prevention & control, Kluyveromyces drug effects, Kluyveromyces metabolism, Lactose metabolism, Quinolones analysis, Quinolones chemistry, Tetracyclines analysis, Tetracyclines chemistry, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents pharmacology, Food Microbiology methods, Hot Temperature, Kluyveromyces growth & development, Whey chemistry
- Abstract
The objective of the studies reported in this research communication was to investigate the use of whey contaminated with antibiotics such as cephalosporins, quinolones and tetracyclines as a nutrient medium for the growth of Kluyveromyces marxianus with particular attention to the effect of thermal treatment used to overcome the inhibitory effects of antibiotic concentrations close to the Maximum Residue Limits. The heat treatments at 120 °C for 40 min, 120 °C for 83 min, and 120 °C for 91 min caused total inactivation of cephalosporins, tetracyclines and quinolone residues in whey respectively.
- Published
- 2019
- Full Text
- View/download PDF
33. Epidemiology of haemolytic uremic syndrome in children. Data from the North Italian HUS network.
- Author
-
Ardissino G, Salardi S, Colombo E, Testa S, Borsa-Ghiringhelli N, Paglialonga F, Paracchini V, Tel F, Possenti I, Belingheri M, Civitillo CF, Sardini S, Ceruti R, Baldioli C, Tommasi P, Parola L, Russo F, and Tedeschi S
- Subjects
- Adolescent, Child, Child, Preschool, Escherichia coli Infections complications, Hemolytic-Uremic Syndrome microbiology, Humans, Incidence, Infant, Italy epidemiology, Escherichia coli isolation & purification, Escherichia coli Infections epidemiology, Hemolytic-Uremic Syndrome epidemiology
- Abstract
Unlabelled: Despite the severity of HUS and the fact that it represents a leading cause of acute kidney injury in children, the general epidemiology of HUS is all but well documented. The present study provides updated, population-based, purely epidemiological information on HUS in childhood from a large and densely populated area of northern Italy (9.6 million inhabitants, 1.6 million children). We systematically reviewed the files concerning patients with STEC-HUS and atypical HUS (aHUS) over a 10-year observation period (January 2003-December 2012). We included all incident cases with a documented first episode of HUS before the age of 18 years. We identified 101 cases of HUS during the 10 years. The overall mean annual incidence was 6.3 cases/million children aged <18 years (range 1.9-11.9), and 15.7/million of age-related population (MARP) among subjects aged <5 years; aHUS accounted for 11.9 % of the cases (mean incidence 0.75/MARP). The overall case fatality rate was 4.0 % (3.4 % STEC-HUS, 8.3 % aHUS)., Conclusion: Given the public health impact of HUS, this study provides recent, population-based epidemiological data useful for healthcare planning and particularly for estimating the financial burden that healthcare providers might have to face in treating HUS, whose incidence rate seems to increase in Northern Italy., What Is Known: • HUS is a rare disease, but it represents the leading cause of acute kidney injury in children worldwide. • STEC-HUS (also called typical, D + HUS) is more common compared to atypical HUS, but recent, population-based epidemiological data (incidence) are scanty. What is New: • Comprehensive, population-based epidemiological data concerning both typical and atypical HUS based on a long observational period.
- Published
- 2016
- Full Text
- View/download PDF
34. [The early management of the sepsis: use of a guidelines document in hospital. Experience at "Carlo Poma" Hospital in Mantova].
- Author
-
Gattuso G, Benazzi D, Ceruti R, Chiarelli C, Nespeca M, Dall'Oglio D, Lonati G, Marchioni M, Sgarioto V, Storti P, Tomasoni D, Castelli G, and Costa P
- Subjects
- Early Diagnosis, Hospitals, Humans, Italy, Sepsis diagnosis, Sepsis mortality, Treatment Outcome, Practice Guidelines as Topic, Sepsis therapy
- Abstract
Today the sepsis represents a very important clinical entity. The Surviving Sepsis Campaign assessed an incidence of sepsis equal to 3 cases/1,000 inhabitants. In UK more than 30,000 cases of severe sepsis are calculated; furthermore the patients with sepsis are increasing worldwide (near 18 millions of cases per year). Because of its high mortality, the sepsis represents one of the main causes of death in the world, also in the developing countries where it causes near sixty percent of the total deaths yearly. The early diagnosis and therapy are very important elements for the outcome of the patients. The Authors present the results of the adoption in their hospital of a guidelines document for the management of the septic patient, that show a decrease of their mortality due to the early diagnosis and specific treatments.
- Published
- 2015
- Full Text
- View/download PDF
35. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
- Author
-
Sabatino MA, Geroni C, Ganzinelli M, Ceruti R, and Broggini M
- Subjects
- Animals, Cell Line, Tumor, Cytidine therapeutic use, Gene Expression Regulation, Neoplastic, Glutathione Transferase metabolism, Humans, Male, Mice, Prostatic Neoplasms pathology, Random Allocation, Xenograft Model Antitumor Assays, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Cytidine analogs & derivatives, DNA Methylation, Glutathione Transferase genetics, Guanidines therapeutic use, Prostatic Neoplasms drug therapy, Prostatic Neoplasms genetics, Pyrroles therapeutic use
- Abstract
Brostallicin is a DNA minor groove binder that shows enhanced antitumor activity in cells with high glutathione S-transferase (GST)/glutathione content. Prostate cancer cells present, almost invariably, methylation of the GSTP1 gene promoter and, as a consequence, low levels of GST-pi expression and activity. In these cells, brostallicin shows very little activity. We tested whether pretreatment of heavily GST-methylated prostate cancer cells with demethylating agents could enhance the activity of brostallicin. Human prostate cancer cells LNCaP and DU145 were used for these studies both in vitro and in vivo. The demethylating agent zebularine was used in combination with brostallicin. Methylation specific PCR and pyrosequencing were used to determine the level of GST methylation. Pretreatment with demethylating agents enhanced the in vitro activity of brostallicin in LNCaP cells. Zebularine, in particular, induced an enhancement of activity in vivo comparable to that obtained by transfecting the human GSTP1 gene in LNCaP cells in vitro. Molecular analysis performed on tumor xenografts in mice pretreated with zebularine failed to detect re-expression of GST-pi and demethylation of GSTP1. However, we found demethylation in the GSTM1 gene, with consequent re-expression of GST-mu at the mRNA level. These results indicate that zebularine, both in vitro and in vivo, enhances the activity of brostallicin and that this enhancement correlates with re-expression of GST-pi and GST-mu. These findings highlight the potential therapeutic value of combining demethylating agents and brostallicin in tumors with GST methylation that poorly respond to brostallicin.
- Published
- 2013
- Full Text
- View/download PDF
36. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
- Author
-
Casolaro A, Golay J, Albanese C, Ceruti R, Patton V, Cribioli S, Pezzoni A, Losa M, Texido G, Giussani U, Marchesi F, Amboldi N, Valsasina B, Bungaro S, Cazzaniga G, Rambaldi A, Introna M, Pesenti E, and Alzani R
- Subjects
- Adult, Animals, Cell Cycle Proteins metabolism, Humans, Leukemia, Myeloid, Acute enzymology, Leukemia, Myeloid, Acute pathology, Mice, Mice, Inbred NOD, Mice, SCID, Neoplasms, Experimental enzymology, Neoplasms, Experimental pathology, Protein Serine-Threonine Kinases metabolism, Proto-Oncogene Proteins metabolism, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, Polo-Like Kinase 1, CD56 Antigen, Cell Cycle Proteins antagonists & inhibitors, Leukemia, Myeloid, Acute drug therapy, Neoplasms, Experimental drug therapy, Protein Kinase Inhibitors pharmacology, Protein Serine-Threonine Kinases antagonists & inhibitors, Proto-Oncogene Proteins antagonists & inhibitors, Pyrazoles pharmacology, Quinazolines pharmacology
- Abstract
CD56 is expressed in 15-20% of acute myeloid leukaemias (AML) and is associated with extramedullary diffusion, multidrug resistance and poor prognosis. We describe the establishment and characterisation of a novel disseminated model of AML (AML-NS8), generated by injection into mice of leukaemic blasts freshly isolated from a patient with an aggressive CD56(+) monoblastic AML (M5a). The model reproduced typical manifestations of this leukaemia, including presence of extramedullary masses and central nervous system involvement, and the original phenotype, karyotype and genotype of leukaemic cells were retained in vivo. Recently Polo-Like Kinase 1 (PLK1) has emerged as a new candidate drug target in AML. We therefore tested our PLK1 inhibitor NMS-P937 in this model either in the engraftment or in the established disease settings. Both schedules showed good efficacy compared to standard therapies, with a significant increase in median survival time (MST) expecially in the established disease setting (MST = 28, 36, 62 days for vehicle, cytarabine and NMS-P937, respectively). Importantly, we could also demonstrate that NMS-P937 induced specific biomarker modulation in extramedullary tissues. This new in vivo model of CD56(+) AML that recapitulates the human tumour lends support for the therapeutic use of PLK1 inhibitors in AML.
- Published
- 2013
- Full Text
- View/download PDF
37. Astroviruses as causative agents of poultry enteritis: genetic characterization and longitudinal studies on field conditions.
- Author
-
Canelli E, Cordioli P, Barbieri I, Catella A, Pennelli D, Ceruti R, Moreno A, and Lavazza A
- Subjects
- Amino Acid Sequence, Animals, Astroviridae Infections diagnosis, Astroviridae Infections virology, Avastrovirus chemistry, Avastrovirus isolation & purification, DNA, Viral analysis, DNA, Viral genetics, Enteritis diagnosis, Enteritis virology, Feces virology, Galliformes, Italy, Microscopy, Electron veterinary, Molecular Sequence Data, Phylogeny, Poultry Diseases virology, RNA, Viral analysis, RNA, Viral genetics, Reverse Transcriptase Polymerase Chain Reaction, Sequence Analysis, RNA, Species Specificity, Astroviridae Infections veterinary, Avastrovirus classification, Avastrovirus genetics, Chickens, Enteritis veterinary, Poultry Diseases diagnosis, Turkeys
- Abstract
Astroviruses (AstVs) are nonenveloped RNA small round viruses (SRVs) with a genome of 6.8-7.9 kb. Known avian AstVs are spread worldwide; they have been associated with poult enteritis and mortality syndrome in the United States and reported in Italy in intensive turkey and guinea fowl flocks. Nevertheless, their real prevalence and their pathogenic role in avian enteritis affecting Italian flocks is far from clear. Negative staining electron microscopy (nsEM) is used for the routine diagnosis of avian enteric SRVs, although it cannot distinguish morphologically similar particles. Enzyme-linked immunosorbent assay (ELISA), reverse-transcription PCR (RT-PCR), and genomic sequencing are now used for this specific purpose. We analyzed 329 samples of chicken, turkey, and guinea fowl intestinal contents from Italian poultry flocks. Most samples were from enteritis outbreaks, but we also included samples from three longitudinal studies (one on 11 broiler flocks and the other two on a guinea fowl flock). We first examined the samples with nsEM. SRVs, including AstVs, are often associated with rotaviruses and were the most commonly detected morphotypes in avian enteric diseases. We then analyzed 124 of the samples with an RT-PCR targeting the open reading frame (ORF)-1b of AstV. This gene codes for an RNA-dependent polymerase. We then sequenced and genetically analyzed the RT-PCR positive samples. Phylogenetic analysis distinguished three defined clusters: the first included guinea fowl AstVs and turkey AstVs-2; the second, chicken AstVs; and the third was formed by avian nephritis viruses (ANVs). No strains clustered with turkey AstVs-1. The results indicate that ORF-1b presents certain genetic variability, even among AstVs from the same species. In longitudinal studies, samples retrieved from the same shed were homogeneous, with some exceptions suggesting possible coexistence of different genetic types in the same unit. The finding of ANV-like viruses in commercial guinea fowls underlines the genetic variability of AstVs and strengthens the hypothesis of a varied intraherd situation.
- Published
- 2012
- Full Text
- View/download PDF
38. Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models.
- Author
-
Alzani R, Pedrini O, Albanese C, Ceruti R, Casolaro A, Patton V, Colotta F, Rambaldi A, Introna M, Pesenti E, Ciomei M, and Golay J
- Subjects
- Animals, Antineoplastic Agents pharmacology, Apoptosis, Blotting, Western, Cell Cycle drug effects, Cell Line, Tumor, Disease Models, Animal, Drug Screening Assays, Antitumor, Humans, Immunohistochemistry, Inhibitory Concentration 50, Mice, Mice, SCID, Antineoplastic Agents therapeutic use, Cyclin-Dependent Kinases antagonists & inhibitors, Leukemia drug therapy
- Abstract
Objective: The aim of the work was to determine and characterize, in vitro and in vivo, the therapeutic activity of PHA-793887, a new potent pan-cdk inhibitor, in the context of hematopoietic neoplasms., Materials and Methods: Thirteen leukemic cell lines bearing different cytogenetic abnormalities and normal hematopoietic cells were used in cytotoxicity and colony assays. The drug activity at the molecular level was analyzed by Western blotting. PHA-793887 was also tested in vivo in several leukemia xenograft models., Results: PHA-793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0.3 to 7 microM (mean: 2.9 microM), regardless of any specific chromosomal aberration. At these doses, the drug was not cytotoxic for normal unstimulated peripheral blood mononuclear cells or CD34(+) hematopoietic stem cells. Interestingly, in colony assays PHA-793887 showed very high activity against leukemia cell lines, with an IC(50) <0.1 microM (mean: 0.08 microM), indicating that it has efficient and prolonged antiproliferative activity. PHA-793887 induced cell-cycle arrest, inhibited Rb and nucleophosmin phosphorylation, and modulated cyclin E and cdc6 expression at low doses (0.2-1 microM) and induced apoptosis at the highest dose (5 microM). It was also effective in vivo in both subcutaneous xenograft and primary leukemic disseminated models that better mimic naturally occurring human disease. Interestingly, in one disseminated model derived from a relapsed Philadelphia-positive acute lymphoid leukemia patient, PHA-793887 showed strong therapeutic activity also when treatment was started after establishment of high disease burden., Conclusions: We conclude that PHA-793887 has promising therapeutic activity against acute leukemias in vitro and in vivo.
- Published
- 2010
- Full Text
- View/download PDF
39. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors.
- Author
-
Cohen RB, Jones SF, Aggarwal C, von Mehren M, Cheng J, Spigel DR, Greco FA, Mariani M, Rocchetti M, Ceruti R, Comis S, Laffranchi B, Moll J, and Burris HA
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Aurora Kinases, Benzamides adverse effects, Benzamides pharmacokinetics, Drug Administration Schedule, Enzyme Inhibitors, Female, Granulocyte Colony-Stimulating Factor administration & dosage, Humans, Infusions, Intravenous, Male, Middle Aged, Neoplasms drug therapy, Neutropenia chemically induced, Pyrazoles adverse effects, Pyrazoles pharmacokinetics, Recombinant Proteins, Antineoplastic Agents administration & dosage, Benzamides therapeutic use, Protein Serine-Threonine Kinases antagonists & inhibitors, Pyrazoles therapeutic use
- Abstract
Purpose: This study was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the i.v. pan-aurora kinase inhibitor PHA-739358, danusertib, in patients with advanced solid tumors., Experimental Design: In part 1, patients received escalating doses of danusertib (24-hour infusion every 14 days) without filgrastim (granulocyte colony-stimulating factor, G-CSF). Febrile neutropenia was the dose-limiting toxicity without G-CSF. Further dose escalation was done in part 2 with G-CSF. Blood samples were collected for danusertib pharmacokinetics and pharmacodynamics. Skin biopsies were collected to assess histone H3 phosphorylation (pH3)., Results: Fifty-six patients were treated, 40 in part 1 and 16 in part 2. Febrile neutropenia was the dose-limiting toxicity in part 1 without G-CSF. Most other adverse events were grade 1 to 2, occurring at doses >or=360 mg/m(2) with similar incidence in parts 1 and 2. The maximum tolerated dose without G-CSF is 500 mg/m(2). The recommended phase 2 dose in part 2 with G-CSF is 750 mg/m(2). Danusertib showed dose-proportional pharmacokinetics in parts 1 and 2 with a median half-life of 18 to 26 hours. pH3 modulation in skin biopsies was observed at >or=500 mg/m(2). One patient with refractory small cell lung cancer (1,000 mg/m(2) with G-CSF) had an objective response lasting 23 weeks. One patient with refractory ovarian cancer had 27% tumor regression and 30% CA125 decline., Conclusions: Danusertib was well tolerated with target inhibition in skin at >or=500 mg/m(2). Preliminary evidence of antitumor activity, including a partial response and several occurrences of prolonged stable disease, was seen across a variety of advanced refractory cancers. Phase II studies are ongoing.
- Published
- 2009
- Full Text
- View/download PDF
40. [Epidemiology of ESBL-positive Enterobacteriaceae in Mantova hospital (Italy)].
- Author
-
Gattuso G, Tomasoni D, Palvarini L, Chiarelli C, Nespeca M, Stradoni R, Ceruti R, Ferri F, and Scalzini A
- Subjects
- Adult, Cross Infection microbiology, Enterobacteriaceae enzymology, Enterobacteriaceae Infections microbiology, Escherichia coli enzymology, Escherichia coli isolation & purification, Escherichia coli Infections epidemiology, Escherichia coli Infections microbiology, Hospital Departments statistics & numerical data, Humans, Immunologic Surveillance, Infant, Newborn, Intensive Care Units, Neonatal statistics & numerical data, Italy epidemiology, Klebsiella enzymology, Klebsiella isolation & purification, Klebsiella Infections epidemiology, Klebsiella Infections microbiology, Proteus enzymology, Proteus isolation & purification, Proteus Infections epidemiology, Proteus Infections microbiology, Substrate Specificity, Bacterial Proteins analysis, Cross Infection epidemiology, Enterobacteriaceae isolation & purification, Enterobacteriaceae Infections epidemiology, Hospitals, Urban statistics & numerical data, beta-Lactam Resistance, beta-Lactamases analysis
- Abstract
In a retrospective study concerning the epidemiology of extended-spectrum beta-lactamase (ESBL) positive Enterobacteriaceae during 2007-2008 in the wards of the Carlo Poma hospital in Mantova, Mercurio surveillance software was used to detect alert microorganisms. Our objective was to link the epidemiological data with the type of patient and ward, and to assess the risk factors for such infections in particular nosocomial environments. The study enabled the change in the relative epidemiological data to be detected, and showed that such bacteria can be found almost throughout the hospital.
- Published
- 2009
41. Immunohistopathological and neuroimaging characterization of murine orthotopic xenograft models of glioblastoma multiforme recapitulating the most salient features of human disease.
- Author
-
Radaelli E, Ceruti R, Patton V, Russo M, Degrassi A, Croci V, Caprera F, Stortini G, Scanziani E, Pesenti E, and Alzani R
- Subjects
- Animals, Cell Line, Tumor, Disease Models, Animal, Humans, Mice, Mice, Nude, Neoplasm Transplantation, Radiography, Brain Neoplasms diagnostic imaging, Brain Neoplasms metabolism, Brain Neoplasms pathology, Glioblastoma diagnostic imaging, Glioblastoma metabolism, Glioblastoma pathology, Immunohistochemistry, Magnetic Resonance Imaging, Xenograft Model Antitumor Assays methods
- Abstract
Tumorigenesis in human glioblastoma multiforme (GBM) is driven by several genetic abnormalities with disruption of important molecular pathways, such as p53/MDM2/p14ARF and EGFR/PTEN/Akt/mTOR. The malignant progression of human GBM is also primarily associated with a peculiar multistep pathophysiological process characterized by intratumoral ischemic necrosis (i.e. pseudopalisading necrosis) and activation of the hypoxia-inducible factor (HIF)-1alpha pathway with consequent peritumoral microvascular proliferation and infiltrative behaviour. Predictable preclinical animal models of GBM should recapitulate the main pathobiological hallmarks of the human disease. In this study we describe two murine orthotopic xenograft models using U87MG and U251 human cell lines. Ten Balb/c nude male mice were orthotopically implanted with either U87MG (5 mice) or U251 (5 mice) cell lines. Intracranial tumor growth was monitored through Magnetic Resonance Imaging (MRI). Immunohistopathological examination of the whole cranium was performed 30 days after implantation. U251 orthotopic xenografts recapitulated the salient pathobiological features described for human GBM, including invasive behaviour, wide areas of pseudopalisading necrosis, florid peripheral angiogenesis, GFAP and vimentin expression, nonfunctional p53 expression, striking active-caspase-3 and HIF-1alpha expression along pseudopalisades. U87MG orthotopic xenografts proved to be very dissimilar from human GBM, showing expansile growth, occasional necrotic foci without pseudopalisades, intratumoral lacunar pattern of angiogenesis, lack of GFAP expression, functional p53 expression and inconsistent HIF-1alpha expression. Expression of pAkt was upregulated in both models. The results obtained suggest that the U251 orthotopic model may be proposed as a predictive and reliable tool in preclinical studies since it recapitulates the most salient pathobiological features reported for human GBM.
- Published
- 2009
- Full Text
- View/download PDF
42. Genetic and antigenic characterization of infectious bursal disease viruses isolated in Italy during the period 2002-2005.
- Author
-
Martin AM, Fallacara F, Barbieri I, Tosi G, Rivallan G, Eterradossi N, Ceruti R, and Cordioli P
- Subjects
- Amino Acid Sequence, Animals, Birnaviridae Infections epidemiology, Birnaviridae Infections virology, Enzyme-Linked Immunosorbent Assay, Italy epidemiology, Molecular Sequence Data, Neutralization Tests, Phylogeny, Poultry Diseases epidemiology, Time Factors, Viral Structural Proteins chemistry, Viral Structural Proteins genetics, Antigens, Viral genetics, Birnaviridae Infections veterinary, Chickens, Infectious bursal disease virus genetics, Poultry Diseases virology
- Abstract
During the period 2002-2005, 109 infectious bursal disease virus (IBDV) field strains were isolated from bird flocks located in various parts of Italy. Out of these strains, 91 were isolated from broilers, 12 from pullets, and six from backyard flocks. Forty-two IBDV strains were further investigated and characterized on the basis of the geographical origin, source, and clinical signs. Antigenic and genetic characterizations were carried out using a monoclonal antibody (MAb)-based antigen-capture (AC) enzyme-linked immunosorbent assay (ELISA) or a virus neutralization assay and a reverse transcription, amplification, and direct sequencing of a genome fragment encoding the VP2 variable domain. The viruses were compared with reference IBDV strains, F52/70 (classical, 1970), 89163 (typical very virulent [vv]IBDV, 1989), 91168 (antigenically modified vvIBDV, 1991) and 94432 (antigenically modified vvIBDV, 1994) among others. All 42 strains were genetically characterized, and the comparison of their nucleotide sequences revealed the presence of six clusters having 100% identity, named group 1, 2, 3, 4, 5, and 6. Twelve strains, representative of each molecular group and/or with interesting amino acid sequence, were also antigenically characterized. The antigenic characterization showed six strains--151573, 157185 (group 1), 192294 (group 2), 77882 (group 3), 217 (group 4), and 192304--with the profile typical of vvIBDV (lack of binding of MAbs 3 and 4). Two strains, 77165 and 204875 (group 6), were also related to vvIBDV but did not react with MAb 5. Three isolates exhibited a profile of cell culture-adapted viruses and classical strains but with some differences: strain 157776 reacted with all MAbs; strain 168026 with all MAbs except MAb 4, which weakly neutralized it; and strain 72293 with all MAbs except MAb 9, which is rather unusual. The last strain, 213622, showed a very uncommon antigenic profile with missing or reduced binding of MAbs 3, 4, 5, 6, 8, and 9. Genetic characterization revealed 37 strains identified as vvIBDV viruses divided in 26 isolates (including groups 1, 2, 3, and 4) with the four amino acids residues typical of vvIBDV (222A, 256I, 294I, 299S) and 11 isolates (including groups 5, 6, and 213622) with some other amino acid exchanges. Four isolates (72293, 168026, 196783, and 222220) presented an amino acid sequence closely related to attenuated classical viruses whereas the last isolate (157776) exhibited a rather different sequence with some mutations typical of vvIBDV and others for cell culture-adapted viruses. Results of the antigenic and genetic characterization revealed that the majority of viruses (n = 37) were related to vvIBDV strains but, among these, 11 strains presented antigenically and genetically modified characteristics and originated, in major part, from the area where viruses have been circulating for a long time. The remaining viruses (n = 5) were related but not identical to attenuated classical viruses and came from areas where vaccination with intermediate strains is applied.
- Published
- 2007
- Full Text
- View/download PDF
43. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.
- Author
-
Carpinelli P, Ceruti R, Giorgini ML, Cappella P, Gianellini L, Croci V, Degrassi A, Texido G, Rocchetti M, Vianello P, Rusconi L, Storici P, Zugnoni P, Arrigoni C, Soncini C, Alli C, Patton V, Marsiglio A, Ballinari D, Pesenti E, Fancelli D, and Moll J
- Subjects
- Animals, Aurora Kinase B, Aurora Kinases, Benzamides pharmacokinetics, Benzamides therapeutic use, Cell Line, Tumor, Cell Proliferation drug effects, Female, Humans, Immunohistochemistry, Male, Mice, Mice, Nude, Neoplasms enzymology, Phosphorylation, Pyrazoles pharmacokinetics, Pyrazoles therapeutic use, Rats, Rats, Sprague-Dawley, Benzamides pharmacology, Neoplasms drug therapy, Protein Serine-Threonine Kinases antagonists & inhibitors, Pyrazoles pharmacology
- Abstract
PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and mechanism of action in cells in vitro and in vivo. p53 status-dependent endoreduplication is observed upon treatment of cells with PHA-739358, and phosphorylation of histone H3 in Ser(10) is inhibited. The compound has significant antitumor activity in different xenografts and spontaneous and transgenic animal tumor models and shows a favorable pharmacokinetic and safety profile. In vivo target modulation is observed as assessed by the inhibition of the phosphorylation of histone H3, which has been validated preclinically as a candidate biomarker for the clinical phase. Pharmacokinetics/pharmacodynamics modeling was used to define drug potency and to support the prediction of active clinical doses and schedules. We conclude that PHA-739358, which is currently tested in clinical trials, has great therapeutic potential in anticancer therapy in a wide range of cancers.
- Published
- 2007
- Full Text
- View/download PDF
44. [Prevention of nosocomial infections: surveillance based on microbiological data].
- Author
-
Gattuso G, Tomasoni D, Palvarini L, Chiarelli C, Stradoni R, Ceruti R, and Scalzini A
- Subjects
- Candidiasis epidemiology, Candidiasis microbiology, Cross Infection epidemiology, Cross Infection microbiology, Humans, Incidence, Italy epidemiology, Microbial Sensitivity Tests, Pseudomonas Infections epidemiology, Pseudomonas Infections microbiology, Pseudomonas aeruginosa isolation & purification, Staphylococcal Infections epidemiology, Staphylococcal Infections microbiology, Staphylococcus aureus isolation & purification, Candidiasis prevention & control, Cross Infection prevention & control, Intensive Care Units, Population Surveillance, Pseudomonas Infections prevention & control, Staphylococcal Infections prevention & control
- Abstract
Background: In the C. Poma Hospital of Mantua we have been using a system of continuous surveillance of nosocomial infections based on microbiological data for the past 4 years. This monitoring estimates the incidence of the microorganisms found in cultures, especially those at risk of causing nosocomial infections., Materials and Methods: Since June 2001 microbiological data have been registered using the Mercurio-Dianoema software and elaborated by means of Microsoft Excel in order to obtain information about isolated bacteria, especially those resistant to antibiotics., Results: Surveillance in "critical" wards revealed the presence of Pseudomonas aeruginosa, Staphylococcus aureus and Candida albicans in the intensive care unit in the period 2003-2005. The most frequent bacteria in hemodialysis have been coagulase-negative Staphylococci and Staphylococcus aureus, with variable methicillin resistance., Conclusion: The analysis of microbiological data has promoted effective measures to reduce the incidence of these bacteria (increased rules of good practice, hand washing, etc.). If nosocomial infections or high-risk microorganisms occur, assessments are carried out; monitoring of the antibiotic resistance of the bacteria is very important.
- Published
- 2007
45. Magnetic resonance imaging and histopathological characterization of prostate tumors in TRAMP mice as model for pre-clinical trials.
- Author
-
Degrassi A, Russo M, Scanziani E, Giusti A, Ceruti R, Texido G, and Pesenti E
- Subjects
- Adenocarcinoma drug therapy, Animals, Antibiotics, Antineoplastic pharmacology, Disease Progression, Doxorubicin pharmacology, Drug Evaluation, Preclinical, Female, Male, Mice, Mice, Inbred C57BL, Prostatic Neoplasms drug therapy, Adenocarcinoma pathology, Disease Models, Animal, Magnetic Resonance Imaging, Mice, Transgenic, Prostatic Neoplasms pathology
- Abstract
Background: The Transgenic Adenocarcinoma of Mouse Prostate (TRAMP) develops progressive forms of prostate cancer. Due to the lack of a validated non-invasive methodology, pathology has been so far the most common parameter evaluated in efficacy studies., Methods: We studied by magnetic resonance imaging (MRI) 210 mice that were repeatedly measured up to 33 weeks of age in order to stage prostate tumors and follow pathological progression in single animals. A pre-clinical trial with doxorubicin was also performed., Results: Progressive forms of cancer (well and poorly differentiated (PD) adenocarcinomas) were easily recognized on MR images and MRI findings were validated against histopathological analysis. Age at tumor onset was different for the two tumoral forms. Doxorubicin treatment caused a strong reduction in tumor volume., Conclusions: Prostate cancer in TRAMP mice is multifocal and heterogeneous: a non-invasive methodology such as MRI facilitates the rational design of translational pre-clinical trials in this widely used animal model.
- Published
- 2007
- Full Text
- View/download PDF
46. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.
- Author
-
Soncini C, Carpinelli P, Gianellini L, Fancelli D, Vianello P, Rusconi L, Storici P, Zugnoni P, Pesenti E, Croci V, Ceruti R, Giorgini ML, Cappella P, Ballinari D, Sola F, Varasi M, Bravo R, and Moll J
- Subjects
- Animals, Antineoplastic Agents chemistry, Antineoplastic Agents therapeutic use, Aurora Kinase B, Aurora Kinases, Biomarkers, Tumor antagonists & inhibitors, Biomarkers, Tumor metabolism, Cell Cycle drug effects, Cell Line, Tumor, Cell Proliferation drug effects, Disease Models, Animal, Dose-Response Relationship, Drug, Drug Screening Assays, Antitumor, Enzyme Inhibitors chemistry, Enzyme Inhibitors therapeutic use, HL-60 Cells, HeLa Cells, Humans, Inhibitory Concentration 50, Mice, Mice, Transgenic, Molecular Structure, Phenotype, Phosphorylation drug effects, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism, Pyrazoles therapeutic use, Pyrroles therapeutic use, Recombinant Proteins antagonists & inhibitors, Recombinant Proteins genetics, Recombinant Proteins metabolism, Reverse Transcriptase Polymerase Chain Reaction methods, Antineoplastic Agents pharmacology, Enzyme Inhibitors pharmacology, Mammary Neoplasms, Experimental drug therapy, Protein Serine-Threonine Kinases antagonists & inhibitors, Pyrazoles pharmacology, Pyrroles pharmacology
- Abstract
Purpose: Aurora kinases play critical roles during mitosis in chromosome segregation and cell division. The aim of this study was to determine the preclinical profile of a novel, highly selective Aurora kinase inhibitor, PHA-680632, as a candidate for anticancer therapy., Experimental Design: The activity of PHA-680632 was assayed in a biochemical ATP competitive kinase assay. A wide panel of cell lines was evaluated for antiproliferative activity. Cell cycle analysis. Immunohistochemistry, Western blotting, and Array Scan were used to follow mechanism of action and biomarker modulation. Specific knockdown of the targets by small interfering RNA was followed to validate the observed phenotypes. Efficacy was determined in different xenograft models and in a transgenic animal model of breast cancer., Results: PHA-680632 is active on a wide range of cancer cell lines and shows significant tumor growth inhibition in different animal tumor models at well-tolerated doses. The mechanism of action of PHA-680632 is in agreement with inhibition of Aurora kinases. Histone H3 phosphorylation in Ser10 is mediated by Aurora B kinase, and our kinetic studies on its inhibition by PHA-680632 in vitro and in vivo show that phosphorylation of histone H3 is a good biomarker to follow activity of PHA-680632., Conclusions: PHA-680632 is the first representative of a new class of Aurora inhibitors with a high potential for further development as an anticancer therapeutic. On treatment, different cell lines respond differentially, suggesting the absence of critical cell cycle checkpoints that could be the basis for a favorable therapeutic window.
- Published
- 2006
- Full Text
- View/download PDF
47. [Epidemiologic surveillance of multi-drug resistant Pseudomonas aeruginosa in Mantova Hospital (Italy)].
- Author
-
Tomasoni D, Gattuso G, Chiarelli C, Palvarini L, Ceruti R, Berra D, Stradoni R, and Scalzini A
- Subjects
- Body Fluids microbiology, Cross Infection epidemiology, Cross Infection prevention & control, Hospital Departments statistics & numerical data, Hospitals, Urban statistics & numerical data, Humans, Italy epidemiology, Prospective Studies, Pseudomonas Infections epidemiology, Pseudomonas Infections prevention & control, Pseudomonas aeruginosa isolation & purification, Cross Infection microbiology, Drug Resistance, Multiple, Bacterial, Population Surveillance, Pseudomonas Infections microbiology, Pseudomonas aeruginosa drug effects
- Abstract
For the period 2002-2005 we verified and compared the data of the prevalence and resistance of Pseudomonas aeruginosa (PA) isolated in Mantova Hospital (Italy) with the data from the international database. From the first six-month period of 2004 a significant increase was found (9% vs 28.8%) in the prevalence of multi-drug resistant PA (MDR-PA). The principal wards involved were the Intensive Care Unit and the Department of Respiratory Diseases. A significant increase in resistance rates was observed for all antimicrobials tested, in particular for aztreonam, ceftazidime, ciprofloxacin, gentamycin and imipenem. The lowest dual resistance rates were observed between amikacina with piperacillin/tazobactam, while the highest were for those that included ciprofloxacin and beta-lactams (aztreonam, cefepime). In this study we confirm the importance of continuous surveillance of laboratory data and tightening local control measures for nosocomial infections in order to prevent the spread and selection of MDR-PA.
- Published
- 2006
48. Klinefelter's syndrome and juvenile chronic arthritis.
- Author
-
Mirkinson LJ, Ceruti R, and Katona IM
- Subjects
- Adolescent, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Arthritis, Juvenile drug therapy, Arthritis, Juvenile physiopathology, Humans, Klinefelter Syndrome diagnosis, Klinefelter Syndrome physiopathology, Male, Methotrexate therapeutic use, Treatment Outcome, Arthritis, Juvenile complications, Klinefelter Syndrome complications
- Published
- 2006
- Full Text
- View/download PDF
49. Enterobacter cloacae in an Italian Neonatal Intensive Care Unit: pattern of drug resistance compared with an international database (SENTRY Antimicrobial Surveillance Program).
- Author
-
Tomasoni D, Gattuso G, Scalzini A, Ceruti R, Chiarelli C, Stradoni R, Bottura C, and Berra D
- Published
- 2006
- Full Text
- View/download PDF
50. Multiresistant Stenotrophomonas maltophilia tunneled CVC-related sepsis, treated with systemic and lock therapy.
- Author
-
Gattuso G, Tomasoni D, Ceruti R, and Scalzini A
- Subjects
- Bacteremia diagnosis, Bacteremia etiology, Bacteremia pathology, Catheterization, Central Venous adverse effects, Cross Infection diagnosis, Cross Infection drug therapy, Cross Infection etiology, Cross Infection pathology, Diagnosis, Differential, Drug Administration Schedule, Equipment Contamination, Gram-Negative Bacterial Infections diagnosis, Gram-Negative Bacterial Infections etiology, Gram-Negative Bacterial Infections pathology, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Anti-Bacterial Agents administration & dosage, Bacteremia drug therapy, Drug Resistance, Bacterial, Gram-Negative Bacterial Infections drug therapy, Stenotrophomonas maltophilia drug effects, Teicoplanin administration & dosage
- Abstract
In the last decade, a remarkable increase in the incidence of nosocomial Gram-negative infections has been observed. These pathogens represent a substantial problem in clinical practice, due to the high resistance profile of most commonly used antibiotics. This phenomenon is surely a co-factor that exposes these susceptible patients to infections caused by selected pathogens like multiresistant Gram-negative rods. A typical example is represented by VAP (ventilator-associated pneumonia) sustained by Acinetobacter spp., Pseudomonas aeruginosa, Bulkolderia cepacia. The Authors describe a case of a central venous cather (CVC)-related Stenotrophomonas maltophilia sepsis in a patient affected by solid tumor, successfully treated with systemic antibiotic therapy associated with "lock therapy". This combination was able to cure the infection, allowing the patient to continue chemotherapy and saving the in situ CVC. The surveillance of CVCs, good adherence to the protocols and guidelines and "good practice" are the cornerstones for the prevention of nosocomial infections.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.